Dermaliq Announced Results From its Phase 1b/2a Trial For DLQ01 For Androgenic Alopecia
Dermaliq, a clinical-stage dermatology and aesthetics company, has announced topline results from their Phase 1b/2a trial evaluating DLQ01, a topical prostaglandin F2 alpha analog, for the treatment of androgenic alopecia in men.
What is DLQ01?
DLQ01 is a topical treatment indicated for male and female pattern baldness that utilizes Dermaliq’s proprietary hyliQ® technology. This formulation contains a prostaglandin F2 alpha (PGF2α) analog designed to promote hair growth on the scalp. PGF2α analogs are synthetic compounds that mimic the structure and function of naturally occurring PGF2α. Other PGF2α analogs are latanoprost, bimatoprost, and isopropyl unoprostone, which have been used in hair loss studies.
When used as a hair loss treatment, these analogs bind to specific prostaglandin receptors on hair follicle cells. Activation of these receptors triggers a cascade of intracellular signaling pathways that can promote hair growth. Furthermore, PGF2α analogs can improve blood flow to the scalp and hair follicles, providing essential nutrients and oxygen that support hair growth and follicle health.
Trial Results
According to the press release, 120 men aged between 18 and 60 (Norwood-Hamilton, vertex grades III-V) were recruited for this study. The participants were randomized into four groups:
- DLQ01
- Low dose DLQ01
- DLQ01 vehicle
- Minoxidil 5%
Participants who applied the DLQ01 treatment showed a significant increase in total area hair count (TAHC) of 12.3% from the baseline compared to the vehicle control. Furthermore, 83% of participants showed a “positive change in hair growth”. The 5% minoxidil treatment increased TAHC by 9.8% compared to the baseline.
In terms of safety, both DLQ01 treatments were well-tolerated.
Dermaliq says that they have “identified a clear regulatory pathway to approval that we will now discuss further with the FDA”.
Reflections
The recent topline results from Dermaliq’s trial are promising, however, several unanswered questions remain:
- Long-Term Efficacy and Safety: While the trial demonstrated positive short-term results, it is crucial to understand the sustainability of these effects over extended periods. Long-term safety profiles are equally important to identify potential adverse effects from prolonged use.
- Dosing Regimen Optimization: The trial included a low-dose DLQ01 group, but the results from this treatment group weren’t mentioned in the press release. Further studies are needed to fine-tune the dosing regimen to achieve the best balance between efficacy and safety.
- Gender and Age Variability: The current study focused on men aged 18-60. Given that androgenic alopecia affects both genders and various age groups, additional studies are necessary to evaluate DLQ01’s efficacy and safety across a broader demographic.
Let us know what you think about these results in the comments.
Posted in Dermaliq, Hair Growth Treatment, Hair Loss Treatment
It is a topical product……does this mean that this product could be approved much faster than an oral or intravenous product?
as always when will jt be available and how much?
When ????? I’ll try anything.
Excellent, looking forward to the 1c/2b trial results next year!
I saw it on the internet
Prostaglandins and baldness, the solution from AI. Korean researchers used a joint artificial intelligence (AI) drug development program to identify substances active in inhibiting prostaglandins associated with common baldness
Cost.
Remind me in 10 years lol
KX-826 Hair Growth Spray Launched
Now the product is for sale on Amazon at a price of $69 for a 1-month supply
https://www.amazon.com/Thickening-Reduction-Regrowth-Treatments-American/dp/B0D97LT6MY?&linkCode=sl1&tag=hyperhidrosis-20&linkId=b19133d7510470effd1a76e12c8f3806&language=en_US&ref_=as_li_ss_tl
Thank you for the tip. Hopefully KX-826 (Pyrilutamide) will be shown to be effective and get a lower price.
Can anyone tell me what the difference is in method of hair count? Sometimes they use hairs/cm2, sometimes they use percentages like Dermaliq: 12.3%. How does that compare to f.e. 24.3 hairs/cm2? (Technoderma) Can’t tell which is a better result.
They need to do their test on completely bald areas of the scalp. I have personally in 30 years of hairloss under my belt seen anything grow hair on a bald area. The notion that Rogaine regrew 9.8 new hairs per square centimeter is manure. If I could gain 9.8 hairs per square centimeter I would have a full head of hair.